Close Menu

NEW YORK – TScan Therapeutics said on Tuesday that it has signed a research license and option agreement with Qiagen to develop T cell-based laboratory tests to detect prior exposure to SARS-CoV-2 using discoveries from TScan's high-throughput T-cell receptor (TCR)/target discovery platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.